Merck Global Health Innovation Fund

Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy. This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions.

Merck GHI has $500M under management and provides growth capital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck.

With a vision that data will be the currency in healthcare, GHI invests broadly in digital health. GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation. Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.

Merck Global Health Innovation Fund, established in 2010 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Private Equity, Seed investments across Biotechnology, Pharmaceutical, Health Diagnostics, Financial Services, Venture Capital, Finance, Banking, Health Care, Medical Device, Information Technology. The organization boasts a portfolio of 97 investments, with an average round size of $38.3M and 26 successful exits. Their recent investments include Aviir, Bay City Capital, New Leaf Venture Partners, Aberdare Ventures, Daktari Diagnostics. The highest investment round they participated in was $319.5B. Among their most notable exits are Aviir and Bay City Capital. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.